Vaccitech to Present at the H.C. Wainwright Global Investment Conference
21 May 2022 - 1:30AM
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines, today announced that the Company’s
Chief Executive Officer, Bill Enright, and Chief Financial Officer,
Georgy Egorov, will present at the H.C. Wainwright Global
Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022.
The conference will be held both in person in Miami and virtually.
A live webcast of the presentation can be accessed through
the Events section of the Vaccitech website. Following
the live webcast, a replay will be available at the same
location.
About Vaccitech plcVaccitech (“the Company”) is
a clinical-stage biopharmaceutical company engaged in the discovery
and development primarily of novel immunotherapies for the
treatment of chronic infectious diseases, cancer, autoimmunity and
diseases where the T cell arm of the immune system is believed to
play an important role. The company’s proprietary platforms include
modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other
viral vectors including the well-validated Modified Vaccinia Ankara
(MVA) and synthetic nano-particle technologies (SNAPvax™ and
Syntholytic™). The combination of different technologies in a mix
and match approach (heterologous prime-boost) consistently
generates significantly higher magnitudes of T cells compared with
other technologies and approaches. The company has a broad pipeline
of both clinical and preclinical stage therapeutic programs to
treat solid tumors, chronic viral infections, as well as a few
prophylactic viral vaccine programs. Vaccitech co-invented a
COVID-19 vaccine with the University of Oxford, now approved for
use in many territories and exclusively licensed worldwide to
AstraZeneca through Oxford University Innovation, or OUI. Vaccitech
is entitled to receive a share of all milestones and royalty income
received by OUI from AstraZeneca.
Vaccitech Media contacts:Katja Stout, Scius
Communications (EU)Direct: +44 (0)
7789435990Email: katja@sciuscommunications.com
Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc.
(U.S.)Email: klarch@burnsmc.com / rflamm@burnsmc.com
Georgy Egorov,
VaccitechEmail: georgy.egorov@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Apr 2024 to May 2024
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From May 2023 to May 2024